New Pharmaceuticals research report from CRI is now available from Fast Market Research
PR-Inside.com: 2014-03-22 11:43:57
Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. As people understand more about B-cell and its action mechanism, it is acknowledged that besides B-cell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively.
Full Report Details at
- www.fastmr.com/prod/782008_investigation_report_on_china_rituxim ..
Statistics shows that incidence of non-Hodgkin lymphomas in China has increased steeply from 20/1,000,000 at the end of the 20th century to 70/1,000,000 at present. Autoimmune diseases can harm central nervous system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life-threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such high incidence should be taken seriously by the public.
By the first quarter of 2014, there were no products from local manufacturers on the market, which was completely occupied by Roche. Early 2014, monoclonal antibody drug "recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection" produced by Hisun was approved clinical. It is a generic drug of Roche's monoclonal antibody "Rituximab". Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to CRI's investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 35% from 2005 to 2012. Rituximab is expected to have huge room to grow in future Chinese market.
Through this report, the readers can acquire the following information:
* Market Share of Major Rituximab Manufacturers in China Sample Hospitals
* Sales Price of Rituximab in China Hospital Market
* Market Share of Rituximab by Dosage Form in China Hospital Market
* Incidence of Autoimmune Diseases in China
* Manufacturing Schedule of Rituximab Generic Drug
* Prospect of China Rituximab Market
The following enterprises and people are recommended to purchase this report:
* Monoclonal Antibody APIs and Finished Product Manufacturers
* Medical Institutions
* Investors/Research Institutes Focusing on Monoclonal Antibody Market
Report Table of Contents:
Table of Contents
1 Relevant Concepts of Rituximab
1.2 Sales Status on the Global Market
2 Market Overview of Rituximab in China, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 Investigation on Sales Value of Rituximab in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Rituximab Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Rituximab by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Rituximab in China Hospital Market, 2014
6.1 Hoffmann-La Roche, Inc.
6.2 Roche Diagnostics
6.3 Shanghai Roche Pharmaceutical Co., Ltd.
7 Major Manufacturers of Rituximab in China Market
7.1 Hoffmann-La Roche, Inc.
7.2 Roche Diagnostics
7.3 Shanghai Roche Pharmaceutical Co., Ltd.
8 Prospect of China Rituximab Market, 2014-2018
8.1 Forecast on Incidence of Non-Hodgkin Lymphomas and Autoimmune Diseases
8.2 Forecast on Rituximab Market Size
8.3 Forecast on Rituximab Competition Pattern
Chart Rituximab Products Approved to Market in China, 2014
Chart global Sales Value of Rituximab, 2009-2013
Chart Sales Value of Rituximab in China Hospital Market, 2009-2013
Chart Sales Value of Rituximab by Region in China, 2009-2013
Chart Market Share of Rituximab Enterprises by Sales Value in China, 2009-2013
Chart Price of Rituximab Produced by Hoffmann-La Roche, Inc. in China Hospital Market
Chart Price of Rituximab Produced by Shanghai Roche in China Hospital Market
Chart Forecast on Market Size of Hospital-use Rituximab in China, 2014-2018
Chart Status of Rituximab Generic Drug Market in China
CRI is a research and consulting company located in Shanghai, China, focusing on various industries and markets. It regularly produces a variety of market research reports, industry analytical reports publications covering 11 industries. It also provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financing. View more research from CRI at www.fastmr.com/catalog/publishers.aspx?pubid=1045
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.